TuHURA Biosciences (HURA) 10-Q 14 Nov 24 2025 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Sep. 30, 2024	Nov. 14, 2024
Document Information [Line Items]
Document Type	10-Q
Document Period End Date	Sep. 30, 2024
Amendment Flag	false
Document Fiscal Year Focus	2025
Document Fiscal Period Focus	Q1
Trading Symbol	HURA
Title of 12(b) Security	Common Stock
Security Exchange Name	NASDAQ
Entity Registrant Name	TuHURA Biosciences, Inc./NV,
Entity Central Index Key	0001498382
Current Fiscal Year End Date	--06-30
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		42,284,524,000
Entity Shell Company	false
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Incorporation, State or Country Code	NV
Entity File Number	001-37823
Entity Tax Identification Number	99-0360497
Entity Address, Address Line One	10500 University Dr
Entity Address, Address Line Two	Suite 110
Entity Address, City or Town	Tampa
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33612
City Area Code	813
Local Phone Number	875-6600
Document Quarterly Report	true
Document Transition Report	false
Former Address [Member]
Document Information [Line Items]
Entity Registrant Name	Kintara Therapeutics, Inc.
Entity Address, Address Line One	9920 Pacific Heights Blvd
Entity Address, Address Line Two	Suite 150
Entity Address, City or Town	San Diego
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92121

Condensed Consolidated Interim

Condensed Consolidated Interim Balance Sheet - USD ($) $ in Thousands	Sep. 30, 2024	Jun. 30, 2024
Current assets
Cash and cash equivalents	$ 3,020	$ 4,909
Prepaid expenses, taxes and other receivables	258	414
Clinical trial deposit	205	205
Total current assets	3,483	5,528
Property and equipment, net	657	674
Total assets	4,140	6,202
Current liabilities
Accounts payable and accrued liabilities	2,207	2,207
Total current liabilities	2,257	2,259
Milestone payment liability	188	186
Total liabilities	2,445	2,445
Stockholders' equity
Common stock Authorized 75,000 shares at September 30, 2024 (June 30, 2024 - 75,000), $0.001 par value, Issued and outstanding 1,590 issued at September 30, 2024 (June 30, 2024 - 1,579)	2	2
Additional paid-in capital	163,445	153,358
Accumulated deficit	(162,052)	(159,876)
Accumulated other comprehensive income	21	21
Total stockholders' equity	1,695	3,757
Total liabilities and stockholders' equity	4,140	6,202
Related Party
Current liabilities
Related party payables	50	52
Preferred Stock Series A
Stockholders' equity
Preferred stock	$ 279	279
Preferred Stock Series C
Stockholders' equity
Preferred stock		$ 9,973

Condensed Consolidated Interi_2

Condensed Consolidated Interim Balance Sheet (Parenthetical) - $ / shares	Sep. 30, 2024	Jun. 30, 2024
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	75,000,000	75,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares issued	1,590,000	1,579,000
Preferred Stock Series A
Preferred Stock, shares issued	279,000	279,000
Preferred stock, shares outstanding	279,000	279,000
Preferred Stock Series C
Preferred Stock, shares issued		14,000
Preferred stock, shares outstanding		14,000

Condensed Consolidated Interi_3

Condensed Consolidated Interim Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Expenses
Research and development	$ 252	$ 1,859
General and administrative	1,957	1,103
Operating expenses	(2,209)	(2,962)
Other income (loss)
Foreign exchange	(1)	(2)
Interest, net	49	2
Other income (loss)	48	0
Net loss for the period	(2,161)	(2,962)
Computation of basic loss per share
Net loss	(2,161)	(2,962)
Series A Preferred cash dividend	(2)	(2)
Series C Preferred stock dividend	(13)	(173)
Net loss for the period attributable to common stockholders	$ (2,176)	$ (3,137)
Basic and fully diluted loss per share	$ (1.37)	$ (63.92)
Basic and fully diluted weighted average number of shares	1,586,000	49,000

Condensed Consolidated Interi_4

Condensed Consolidated Interim Statements of Stockholders' Equity (Deficiency) (Unaudited) - USD ($) $ in Thousands	Total	Common stock	Additional paid-in capital	Accumulated other comprehensive income	Preferred stock	Accumulated deficit
Beginning Balance at Jun. 30, 2023	$ 731	$ 1	$ 141,439	$ 21	$ 10,645	$ (151,375)
Beginning Balance, shares at Jun. 30, 2023		48,000
Conversion of Series C Preferred stock to common stock	37		37		(37)
Stock option expense	160		160
Restricted stock unit expense	47		47
Series A Preferred cash dividend	(2)					(2)
Series C Preferred stock dividend			173			(173)
Series C Preferred stock dividend, shares		1,000
Loss for the period	(2,962)					(2,962)
Ending Balance at Sep. 30, 2023	(2,026)	$ 1	141,856	21	10,608	(154,512)
Ending Balance, shares at Sep. 30, 2023		49,000
Beginning Balance at Jun. 30, 2024	3,757	$ 2	153,358	21	10,252	(159,876)
Beginning Balance, shares at Jun. 30, 2024		1,579,000
Issuance of shares on vesting of restricted stock units, shares		2,000
Conversion of Series C Preferred stock to common stock	9,973		9,973		(9,973)
Conversion of Series C preferred stock to common stock, shares		7,000
Stock option expense	98		98
Restricted stock unit expense	3		3
Series A Preferred cash dividend	(2)					(2)
Series C Preferred stock dividend			13			(13)
Series C Preferred stock dividend, shares		2,000
Loss for the period	(2,161)					(2,161)
Ending Balance at Sep. 30, 2024	$ 1,695	$ 2	$ 163,445	$ 21	$ 279	$ (162,052)
Ending Balance, shares at Sep. 30, 2024		1,590,000

Condensed Consolidated Interi_5

Condensed Consolidated Interim Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Cash flows from operating activities
Loss for the period	$ (2,161)	$ (2,962)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation of property and equipment	17	15
Change in fair value of milestone liability	2	1
Stock option expense	98	160
Restricted stock unit expense	3	47
Changes in operating assets and liabilities
Prepaid expenses, taxes and other receivables	156	93
Clinical trial deposit		1,075
Accounts payable and accrued liabilities		214
Related party payables	(4)	40
Net cash used in operating activities	(1,889)	(1,317)
Cash flows from financing activities
Series A Preferred cash dividend		(2)
Net cash provided by financing activities		(2)
Decrease in cash and cash equivalents	(1,889)	(1,319)
Cash and cash equivalents – beginning of period	4,909	1,535
Cash and cash equivalents – end of period	$ 3,020	$ 216

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Pay vs Performance Disclosure
Net Income (Loss)	$ (2,161)	$ (2,962)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Sep. 30, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Nature of operations, corporate

Nature of operations, corporate history, and going concern and management plans	3 Months Ended
	Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of operations, corporate history, and going concern and management plans	1 Nature of operations, corporate history, and going concern and management plans Nature of operations Kintara Therapeutics, Inc., a Nevada corporation (“Kintara” or, the “Company”) is a clinical-stage drug development company with a focus on the development of novel cancer therapies for patients with unmet medical needs. The Company is developing one late-stage therapeutic - REM-001 for cutaneous metastatic breast cancer (“CMBC”). In order to accelerate the Company’s development timelines, it leverages existing preclinical and clinical data from a wide range of sources. The Company may seek marketing partnerships in order to potentially offset clinical costs and to generate future royalty revenue from approved indications of its current and future product candidates. Merger with TuHURA Biosciences, Inc. On April 2, 2024, the Company entered into a definitive Agreement and Plan of Merger with TuHURA Biosciences, Inc., a Delaware corporation (“TuHURA”), and Kayak Mergeco, Inc., a Delaware corporation wholly owned subsidiary the Company (“Merger Sub”), for an all-stock merger transaction (the “Merger”) forming a company with expertise and resources to advance a risk diversified late-stage oncology pipeline (the “Merger Agreement”). The Merger Agreement provided that, upon completion of the Merger, the former TuHURA stockholders would own the majority of the shares of the Company. The Merger and other transactions contemplated by the Merger Agreement closed on October 18, 2024 (see note 10). Unless context otherwise requires, the use of “we,” “us,” “our,” and the “Company” in this Report refers to Kintara Therapeutics, Inc., a Nevada corporation pre-Merger and its wholly owned subsidiaries. Corporate history The Company is a Nevada corporation formed on June 24, 2009, under the name Berry Only, Inc. On January 25, 2013, the Company entered into and closed an exchange agreement (the “Exchange Agreement”), with Del Mar Pharmaceuticals (BC) Ltd. (“Del Mar (BC)”), 0959454 B.C. Ltd. (“Callco”), and 0959456 B.C. Ltd. (“Exchangeco”) and the security holders of Del Mar (BC). Upon completion of the Exchange Agreement, Del Mar (BC) became a wholly-owned subsidiary of the Company (the “Reverse Acquisition”). On August 19, 2020, the Company completed its merger with Adgero Biopharmaceuticals Holdings, Inc., a Delaware corporation (“Adgero”) in which Adgero continued its existence under Delaware law and became a direct, wholly-owned subsidiary of the Company. Following the completion of the merger, the Company changed its name from DelMar Pharmaceuticals, Inc. to Kintara Therapeutics, Inc. and began trading on The Nasdaq Capital Market LLC (“Nasdaq”) under the symbol “KTRA”. Kintara Therapeutics, Inc. is the parent company of Del Mar (BC), a British Columbia, Canada corporation and Adgero, which are clinical-stage companies with a focus on the development of drugs for the treatment of cancer. The Company is also the parent company to Callco and Exchangeco which are British Columbia, Canada corporations. Callco and Exchangeco were formed to facilitate the Reverse Acquisition. In connection with the Adgero merger, the Company also became the parent company of Adgero Biopharmaceuticals, Inc. (“Adgero Bio”), formerly a wholly-owned subsidiary of Adgero. On October 18, 2024, the Company completed its merger with TuHURA and Merger Sub pursuant to the terms of the Merger Agreement. In connection with the Merger, Merger Sub merged with and into TuHURA with TuHURA surviving the Merger as a wholly owned subsidiary of the Company. Following the completion of the Merger, the Company changed its corporate name to “TuHURA Biosciences, Inc.” References to the Company refer to the Company and its wholly-owned subsidiaries. Going concern and management plans These condensed consolidated interim financial statements have been prepared on a going concern basis which assumes that the Company will continue its operations for the foreseeable future and contemplates the realization of assets and the settlement of liabilities in the normal course of business. For the three months ended September 30, 2024, the Company reported a loss of $ 2,161 and a negative cash flow from operations of $ 1,889 . The Company had an accumulated deficit of $ 162,052 and had cash and cash equivalents of $ 3,020 as of September 30, 2024. The Company is in the clinical stage and has not generated any revenues to date. The Company does not have the prospect of achieving revenues until such time that its product candidate is commercialized, or partnered, which may not ever occur. On August 2, 2 022, the Company entered into a stock purchase agreement under which the Company has issued 19 shares of common stock for $ 2,008 in net proceeds as of September 30, 2024. In ad dition, on June 28, 2023, the Company announced that it had been awarded approximately $ 2,000 in grant funding to be received over a two-year period for its REM-001 project. During the year ended June 30, 2024, the Company issued an additional 1,519 shares of common stock for net proceeds of $ 10,471 from its at-the-market ( “ATM”) facility, and announced that it is suspending the development of VAL-083. Even with the proceeds from the grant funding, the stock purchase financing, and the ATM sales, the Company will require additional funding to maintain its clinical trials, research and development projects, and for general operations. These circumstances indicate substantial doubt exists about the Company’s ability to continue as a going concern within one year from the date of filing of these condensed consolidated interim financial statements. On October 18, 2024, the Company completed the Merger with TuHURA, on and subject to the terms of the Merger Agreement (Note 11). Consequently, management is pursuing various financing alternatives to fund the Company’s operations so it can continue as a going concern. Management plans to continue to pursue opportunities to secure the necessary financing through the issue of new equity, including debt, entering into strategic partnership arrangements, and/or pursuing additional strategic transactions. However, the Company’s ability to raise additional capital could be affected by various risks and uncertainties including, but not limited to, global unrest. The Company may not be able to raise sufficient additional capital and may need to tailor its drug candidate development programs based on the amount of funding the Company is able to raise in the future. Nevertheless, there is no assurance that these initiatives will be successful. These condensed consolidated interim financial statements do not give effect to any adjustments to the amounts and classification of assets and liabilities that may be necessary should the Company be unable to continue as a going concern, that may or may not be material to these condensed consolidated interim financial statements.

Significant Accounting Policies

Significant Accounting Policies	3 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
Significant accounting policies	2 Significant accounting policies Reverse stock split On November 10, 2022, the Company filed a Certificate of Change to the Company’s Articles of Incorporation, as amended, in order to effectuate a 1: 50 reverse stock split (the “Reverse Stock Split”) of its issued and outstanding common stock as well as its authorized shares of common stock. As a result of the Reverse Stock Split, every 50 shares of issued and outstanding common stock were converted into one share of common stock with a proportionate reduction in the Company's authorized shares of common stock. Any fractional shares of common stock resulting from the Reverse Stock Split were rounded up to the nearest whole post-Reverse Stock Split share. The Reverse Stock Split did not change the par value of the Company's common stock. All outstanding securities entitling their holders to acquire shares of common stock were adjusted as a result of the Reverse Stock Split. All common share and per share data are retrospectively restated to give effect to the Reverse Stock Split for all periods presented herein. Basis of presentation The condensed consolidated interim financial statements of the Company have been prepared in accordance with United States Generally Accepted Accounting Principles (“U.S. GAAP”) and are presented in United States dollars. The functional currency of the Company and each of its subsidiaries is the United States dollar. The accompanying condensed consolidated interim financial statements include the accounts of the Company and its wholly-owned subsidiaries, Adgero, Adgero Bio, Del Mar (BC), Callco, and Exchangeco. All intercompany balances and transactions have been eliminated in consolidation. The principal accounting policies applied in the preparation of these condensed consolidated interim financial statements are set out below and have been consistently applied to all periods presented. Unaudited interim financial data The accompanying unaudited condensed consolidated interim financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim financial information. Accordingly, they do not include all of the information and the notes required by U.S. GAAP for complete financial statements. These unaudited condensed consolidated interim financial statements should be read in conjunction with the June 30, 2024, audited consolidated financial statements of the Company included in the Company’s Form 10-K filed with the SEC on October 7, 2024. In the opinion of management, the unaudited condensed consolidated interim financial statements reflect all adjustments, consisting of normal and recurring adjustments, necessary for a fair presentation. The results for three months ended September 30, 2024, are not necessarily indicative of the results to be expected for the fiscal year ending June 30, 2025, or for any other future annual or interim period. Use of estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions about future events that affect the reported amounts of assets, liabilities, expenses, contingent assets, and contingent liabilities as at the end of, or during, the reporting period. Actual results could significantly differ from those estimates. Significant areas requiring management to make estimates include the valuation of equity instruments issued for services, milestone payment liability, and clinical trial accruals. Further details of the nature of these assumptions and conditions may be found in the relevant notes to these condensed consolidated interim financial statements. Loss per share Loss per share is calculated based on the weighted average number of common shares outstanding. For the three-month periods ended September 30, 2024, and 2023, diluted loss per share does not differ from basic loss per share since the effect of the Company’s warrants, stock options, restricted stock units, and convertible preferred shares is anti-dilutive. As of September 30, 2024, potential common shares of 17 (2023 – 20 ) related to outstanding common share warrants, nil (2023 – 1 ) related to outstanding Series C preferred stock warrants, 6 (2023 – 8 ) related to stock options, nil (2023 - 2 ) related to restricted stock units, and nil (2023 – 7 ) relating to outstanding Series C convertible preferred shares were excluded from the calculation of net loss per common share. Government assistance Government grants, including grants from similar bodies, are recognized when there is reasonable assurance that the Company has met the requirements of the approved grant program and there is reasonable assurance that the grant will be received. Grants that compensate the Company for expenses incurred are recognized in income or loss in reduction thereof in the same period in which the expenses are recognized. The Company uses a net presentation basis whereby the grant offsets the research and development expenses as it is being recovered under the grant program. Recently issued accounting standards Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company’s condensed consolidated interim financial statements.

Clinical Trial Deposit

Clinical Trial Deposit	3 Months Ended
	Sep. 30, 2024
Other Liabilities [Abstract]
Clinical Trial Deposit	3 Clinical trial deposit In October 2020, the Company announced that it had entered into a final agreement with a contract research organization (“CRO”) for the management of the Company’s registrational study of VAL-083 for glioblastoma. Under the agreement, the Company supplied the drug for the study and the CRO managed all operational aspects of the study including site activation and patient enrollment. The Company was required to make certain payments under the agreement related to patient enrollment milestones. For the three months ended September 30, 2024, the Company has recognized an expense of $ nil (2023 - $ 1,075 ) for this study in relation to clinical site initiation and patient enrollment. On October 31, 2023, the Company announced that preliminary topline results from this registrational study for VAL-083 did not perform better than the current standards of care in glioblastoma. As a result, the Company announced that it has terminated the development of VAL-083. In the year ended June 30, 2024, the remaining deposit of $ 1,075 was offset against amounts owing to the CRO and the agreement with the CRO was terminated with an additional final cost of $ 1,000 , which was paid in the year ended June 30, 2024. As of June 30, 2024, and September 30, 2024, the Company has recorded $ 205 as a deposit with a CRO for the management of the Company’s 15-patient study of REM-001 for cutaneous metastatic breast cancer (“CMBC”).

Clinical Trials Grant

Clinical Trials Grant	3 Months Ended
	Sep. 30, 2024
Share-Based Payment Arrangement [Abstract]
Clinical Trials Grant	4 Clinical trials grant Effective July 1, 2023, the Company was awarded a $ 2,000 Small Business Innovation Research grant from the National Institutes of Health (“NIH”) to support the clinical development of REM-001 for the treatment of CMBC. The grant will be received in two tranches: approximately $ 1,250 for the period July 1, 2023, to June 30, 2024, and approximately $ 750 for the period July 1, 2024, to June 30, 2025. As a result of receiving the grant, the REM-001, 15-patient clinical trial was restarted. The grant is expended to the Company as a reimbursement of expenditures incurred. During the three months ended September 30, 2024, the Company received $ 236 (2023 - $ 13 ) for grants received against research and development expenditures in the period. The grant is subject to various performance conditions and funding risk where the financial conditions of the NIH may change from time to time. The Company recognizes the grant only to the extent there is reasonable assurance the grant will be funded to the Company.

Property and Equipment, Net

Property and Equipment, Net	3 Months Ended
	Sep. 30, 2024
Property, Plant and Equipment [Abstract]
Property and equipment, net	5 Property and equipment, net $ Balance, June 30, 2024 674 Depreciation ( 17 ) Balance, September 30, 2024 657 At September 30, 2024, the total capitalized cost of property and equipment was $ 879 (June 30, 2024 - $ 879 ), of which $ 499 is not in use. The Company has recognized $ 17 (2023 - $ 15 ) in depreciat ion expense in the three months ended September 30, 2024, on equipment in use.

Accounts Payable and Accrued Li

Accounts Payable and Accrued Liabilities	3 Months Ended
	Sep. 30, 2024
Payables and Accruals [Abstract]
Accounts payable and accrued liabilities	6 Accounts payable and accrued liabilities September 30, June 30, Trade payables 1,871 1,464 Accrued liabilities 336 743 Balance 2,207 2,207

Related Party Transactions

Related Party Transactions	3 Months Ended
	Sep. 30, 2024
Related Party Transactions [Abstract]
Related party transactions	7 Related party transactions Valent Technologies, LLC Agreements On November 20, 2023, Dr. Brown was terminated from his position as the Company’s Chief Scientific Officer as a result of cost-cutting measures adopted by the Company; he remains a consultant to the Company. Dr. Brown is a principal of Valent Technologies, LLC (“Valent”) and as a result Valent is a related party to the Company. On September 12, 2010, the Company entered into a Patent Assignment Agreement (the “Valent Assignment Agreement”) with Valent pursuant to which Valent transferred to the Company all its right, title and interest in, and to, the patents for VAL-083 owned by Valent. The Company now owns all rights and title to VAL-083 and is responsible for further development and commercialization. In accordance with the terms of the Valent Assignment Agreement, Valent is entitled to receive a future royalty on all revenues derived from the development and commercialization of VAL-083. In the event that the Company terminates the agreement, the Company may be entitled to receive royalties from Valent’s subsequent development of VAL-083 depending on the development milestones the Company has achieved prior to the termination of the Valent Assignment Agreement. On September 30, 2014, the Company entered into an exchange agreement (the “Valent Exchange Agreement”) with Valent and Del Mar (BC). Pursuant to the Valent Exchange Agreement, Valent exchanged its loan payable in the outstanding amount of $ 279 (including aggregate accrued interest to September 30, 2014, of $ 29 ), issued to Valent by Del Mar (BC), for 279 shares of the Company’s Series A Preferred Stock. The Series A Preferred Stock has a stated value of $ 1.00 per share (the “Series A Stated Value”) and is not convertible into common stock. The holder of the Series A Preferred Stock is entitled to dividends at the rate of 3 % of the Series A Stated Value per year, payable quarterly in arrears. For the three months ended September 30, 2024, the Company recorded $ 2 (2023 - $ 2 ) re lated to the dividends paid to Valent. The dividends have been recorded as a direct increase in accumulated deficit. On February 13, 2024, the Company sent an Opt-Out Notice to Valent under the Valent Assignment Agreement whereby the Company assigned all rights, title and interest in and to the patents for VAL-083 to Valent. As a result, the Company granted Valent a non-exclusive, fully-paid, royalty-free, perpetual, worldwide and non-transferable license, subject to limited exceptions. The Company is entitled to receive royalties from Valent’s subsequent commercialization of VAL-083 equal to 5 % of Valent Net Sales (as defined in the Valent Assignment Agreement). Related party payables As of September 30, 2024, there is an aggregate amount of $ 50 (June 30, 2024 - $ 52 ) payable to the Company’s officers and directors for fees, expenses, and other liabilities.

Stockholders' Equity

Stockholders' Equity	3 Months Ended
	Sep. 30, 2024
Equity [Abstract]
Stockholders' Equity	Stockholders’ equity Preferred stock Series C Preferred Stock Series C Preferred Stock Number $ Balance – June 30, 2024 13,668 9,973 Conversion of Series C Preferred stock to common stock ( 13,668 ) ( 9,973 ) Balance – September 30, 2024 — — In August 2020, the Company issued 25,028 shares of Series C Convertible Preferred Stock (the “Series C Preferred Stock”) in three separate closings of a private placement (Series C-1, C-2, and C-3). Each share of Series C Preferred Stock was issued at a purchase price of $ 1,000 per share and is convertible into shares of common stock based on the respective conversion prices which were determined at the closing of each round of the private placement. The conversion prices for the Series C-1 Preferred Stock, Series C-2 Preferred Stock, and the Series C-3 Preferred Stock were $ 2,030.00 , $ 2,124.50 , and $ 2,012.50 , respectively. Subject to ownership limitations, the owners of the Series C-1 Preferred Stock, the Series C-2 Preferred Stock, and the Series C-3 Preferred Stock were entitled to receive dividends, payable in shares of common stock at a rate of 10 %, 15 %, 20 % and 25 %, respectively, of the number of shares of common stock issuable upon conversion of the Series C Preferred Stock, on the 12th, 24th, 36th and 48th month, anniversary of the initial closing of the private placement. The Company paid the 12th, 24th, 36th, and 48th month anniversary dividends of 10 %, 15 %, 20 %, and 25 % common stock dividends on August 19, 2021, 2022, 2023, and 2024, respectively. The Series C Preferred Stock dividends did not require declaration by the board of directors and were accrued annually as of the date the dividend was earned in an amount equal to the fair value of the Company’s common stock on the dates the respective dividends were paid. The fair value of the Series C Preferred Stock dividend paid on August 19, 2024, was determined by multiplying the dividends paid of 2 shares of common stock by the Company’s closing share price on August 18, 2024, of $7 .93 per share for a total fair value of $ 13 . All outstanding shares of Series C Preferred Stock were automatically converted to an aggregate of 7 shares of common stock on August 19, 2024. In addition, as part of the Series C Preferred financing, the Company issued warrants to the placement agent (“Series C Agent Warrants”), which expired unexercised on August 19, 2024. The Series C Preferred Stock, with respect to distributions of assets and rights upon the occurrence of a liquidation, ranked (i) senior to the Company’s common stock and (ii) senior to any other class or series of capital stock of the Company hereafter created which did not e xpressly rank pari passu with, or senior to, the Series C Preferred Stock. The Series C Preferred Stock was pari passu in liquidation to the Company’s Series A Preferred Stock. The liquidation value of the Series C Preferred Stock at September 30, 2024, is the stated value of $ nil (June 30, 2024 - $ 9,973 ). The Company’s Series C Preferred Stock aggregate dividends as of September 30, 2024, were as follows: Series C Dividends Dividend Shares 10% - August 19, 2021 (actual) 1 15% - August 19, 2022 (actual) 1 20% - August 19, 2023 (actual) 1 25% - August 19, 2024 (actual) 2 5 Series A Preferred Stock Effective September 30, 2014, the Company filed a Certificate of Designation of Series A Preferred Stock (the “Series A Certificate of Designation”) with the Secretary of State of Nevada. Pursuant to the Series A Certificate of Designation, the Company designated 279 shares of preferred stock as Series A Preferred Stock. The shares of Series A Preferred Stock have a stated value of $ 1.00 per share (the “Series A Stated Value”) and are not convertible into common stock. The holder of the Series A Preferred Stock is entitled to dividends at the rate of 3 % of the Series A Stated Value per year, payable quarterly in arrears. Upon any liquidation of the Company, the holder of the Series A Preferred Stock will be entitled to be paid, out of any assets of the Company available for distribution to stockholders, the Series A Stated Value of the shares of Series A Preferred Stock held by such holder, plus any accrued but unpaid dividends thereon, prior to any payments being made with respect to the common stock. The Series A Preferred Stock is held by Valent (note 7). The Series A Preferred Stock shall with respect to distributions of assets and rights upon the occurrence of a liquidation, rank (i) senior to the Company’s common stock, and (ii) senior to any other class or series of capital stock of the Company hereafter created which does not expressly rank pari passu with, or senior to, the Series A Preferred Stock. The Series A Preferred Stock was pari passu in liquidation to the Company’s Series C Preferred Stock. The liquidation value of the Series A Preferred stock at September 30, 2024, is its stated value of $ 279 (June 30, 2024 - $ 279 ). There was no change to the Series A Preferred stock for the three months ended September 30, 2024, or 2023. Common stock Common stock issuances during the three months ended September 30, 2024 During the three months ended September 30, 2024, the Company issued 2 shares of common stock on vesting of restricted stock units during the period. The Company also issued 2 and 7 shares of common stock, representing the Series C Preferred Stock 25 % dividend and automatic conversion of outstanding Series C Preferred Stock, respectively, on the fourth anniversary of issuance. Common stock issuances during the three months ended September 30, 2023 During the three months ended September 30, 2023, the Company issued 2 shares of common stock, representing the Series C Preferred Stock 20 % dividend the third anniversary of issuance. 2017 Omnibus Incentive Plan As subsequently approved by the Company’s stockholders at an annual meeting of stockholders, on April 11, 2018, the Company’s board of directors approved the adoption of the Company’s 2017 Omnibus Equity Incentive Plan (the “2017 Plan”), as amended. The board of directors also approved a form of Performance Stock Unit Award Agreement to be used in connection with grants of performance stock units (“PSUs”) as well as a Restricted Stock Unit ("RSU") award under the 2017 Plan. As approved by the Company’s stockholders on June 21, 2022, the number of common shares available under the 2017 Plan as of September 30, 2024, is 13 shares, less the numbe r of shares of common stock issued under the Del Mar (BC) 2013 Amended and Restated Stock Option Plan (the “Legacy Plan”), or that are subject to grants of stock options made, or that may be made, under the Legacy Plan, or that have been previously exercised. The following table sets forth the aggregate information on all equity compensation plans as of September 30, 2024: Plan (in thousands, except per share amounts) Number of shares of common stock to be issued upon exercise of outstanding stock options and rights Weighted-average exercise price of stock options and rights Number of shares of common stock remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a)) (2) Equity compensation plans approved by security holders - 2017 Plan (1) 6 749.16 4 Equity compensation plans not approved by security holders - Del Mar (BC) 2013 Amended and Restated Stock Option Plan — 73,881.30 — Totals 6 1,074.40 4 (1) The Del Mar (BC) 2013 Amended and Restated Stock Option Plan refers to the Company’s previous equity compensation plan. (2) The balance of 4 shares of common stock available for issuance under the 2017 Plan as of September 30, 2024, is net of stock options previously exercised. The maximum number of shares of Company common stock with respect to which any one participant may be granted awards during any calendar year is 8 % of the Company’s fully diluted shares of common stock on the date of grant (excluding the number of shares of common stock issued under the 2017 Plan and/or the Legacy Plan or subject to outstanding awards granted under the 2017 Plan and/or the Legacy Plan). No award will be granted under the 2017 Plan on, or after, July 7, 2027. Stock options There were no changes in stock options during the three months ended September 30, 2024. The following table summarizes stock options outstanding and exercisable under all plans at September 30, 2024: Exercise price Number Weighted Number 162.93 2 8.92 1 307.65 1 7.84 1 1,067.50 to 1,680.00 2 7.36 2 2,170.00 to 2,397.50 1 2.43 — 6 4 The Company has recognized the following amounts as stock option expense for the periods noted (in thousands): Three months ended 2024 2023 Research and development 37 69 General and administrative 61 91 98 160 All of the stock option expense for the periods ended September 30, 2024, and 2023, has been recognized as additional paid in capital. The aggregate intrinsic value of stock options outstanding as well as stock options exercisable was nil as of September 30, 2024, and 2023, respectively. As of September 30, 2024, there was $ 224 in unrecognized compensation expense that will be recognized over the next 1.8 years. The following table sets forth changes in unvested stock options under all plans: Number of Weighted Unvested at June 30, 2024 3 545.01 Vested ( 1 ) 435.36 Unvested at September 30, 2024 2 579.79 The aggregate intrinsic value of unvested stock options at September 30, 2024, was nil (2023 - nil ). The unvested stock options have a remaining weighted average contractual term of 7.16 years (2023 – 9.26 ). Restricted stock units During the three months ended September 30, 2024, the Company recognized a total of $ 3 (2023 - $ 47 ) in compensation expense related to RSUs. Number of Balance – June 30, 2024 2 Vesting of restricted stock units ( 2 ) Balance – September 30, 2024 — Common stock warrants The following table sets forth changes in outstanding common stock warrants: Number of Weighted Balance – June 30, 2024 19 1,399.72 Expiry of warrants issued for services ( 2 ) 1,750.00 Balance – September 30, 2024 17 1,362.41 The following table summarizes the Company’s outstanding common stock warrants as of September 30, 2024: Description of warrants Number Exercise Expiry date 2022 April Investor warrants 9 717.50 April 14, 2027 2022 Investor warrants 7 2,187.50 March 28, 2025 2022 April Agent warrants 1 1,159.20 October 14, 2026 17 Series C Preferred Stock warrants In connection with the Series C Preferred Stock private placement, the Company issued 2,504 Series C Agent Warrants. The Series C Agent Warrants had an exercise price of $ 1,000 per share, provide for a cashless exercise feature, and wee exercisable for a period of four years from August 19, 2020. The Series C Agent Warrants expired unexercised on August 19, 2024. The Series C Preferred Stock issuable upon exercise of the Series C Agent Warrants were convertible into shares of common stock in the same manner as each respective underlying series of outstanding Series C Preferred Stock and were entitled to the same dividend rights as each respective series. The following table sets forth changes in outstanding Series C Agent Warrants: Balance Number of Balance, Conversion Preferred Series C-1 Agent Warrants 1,929 ( 1,929 ) — 2,030.00 Preferred Series C-2 Agent Warrants 219 ( 219 ) — 2,124.50 Preferred Series C-3 Agent Warrants 296 ( 296 ) — 2,012.50 2,444 ( 2,444 ) —

Supplementary Statement of Cash

Supplementary Statement of Cash Flows Information	3 Months Ended
	Sep. 30, 2024
Supplemental Cash Flow Elements [Abstract]
Supplementary statement of cash flows information	9 Supplementary statement of cash flows information The Company incurred the following non-cash investing and financing transactions (in thousands): Three months ended 2024 2023 Series C Preferred Stock common stock dividend (note 8) 13 173 Series A Preferred Stock cash dividend in accounts payable and accrued liabilities 2 — Conversion of Series C Preferred Stock to common stock (note 8) 9,973 37 Income taxes paid — — Interest paid — —

Financial instruments

Financial instruments	3 Months Ended
	Sep. 30, 2024
Investments, All Other Investments [Abstract]
Financial Instruments	Financial instruments The Company's financial instruments are measured at fair value as determined by using the fair value hierarchy for inputs that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use to value an asset or liability and are developed based on market data obtained from independent sources. Unobservable inputs are inputs based on assumptions about the factors market participants would use to value an asset or liability. The three levels of inputs that may be used to measure fair value are as follows:  Level one - inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities;  Level two - inputs are inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly such as interest rates, foreign exchange rates, and yield curves that are observable at commonly quoted intervals; and  Level three - unobservable inputs developed using estimates and assumptions, which are developed by the reporting entity and reflect those assumptions that a market participant would use. Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. Changes in the observability of valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy. As of September 30, 2024, the Company’s milestone payment liability was measured using level three inputs. The milestone payment liability relates to contingent milestone payments for the REM-001 program that was acquired in the Adgero merger (note 1). September 30, 2024 Liability Level 1 Level 2 Level 3 Milestone payment liability — — 188 $ Balance – June 30, 2024 186 Change in fair value estimate 2 Balance – September 30, 2024 188 The Company’s financial instruments consist of cash and cash equivalents, other receivables, accounts payable, and related party payables. The carrying values of cash and cash equivalents, other receivables, accounts payable and related party payables approximate their fair values due to the immediate or short-term maturity of these financial instruments.

Subsequent Events

Subsequent Events	3 Months Ended
	Sep. 30, 2024
Subsequent Events [Abstract]
Subsequent events	11 Subsequent events The Company has evaluated its subsequent events from September 30, 2024, through the date these condensed consolidated interim financial statements were issued and has determined that there are no subsequent events requiring disclosure in these condensed consolidated interim financial statements other than the items noted below. Amendment to Hoffman Employment Agreement Robert E. Hoffman, former Chief Executive Officer and Interim Chief Financial Officer of the Company, and the Company are parties to a certain Executive Employment Agreement dated November 8, 2021 (the “Hoffman Employment Agreement”). On October 4, 2024, the Company and Mr. Hoffman entered into an amendment to the Hoffman Employment Agreement (the “Hoffman Amendment”). Pursuant to the Hoffman Amendment, all outstanding stock options previously granted to Mr. Hoffman by the Company vested in full on October 4, 2024 in exchange for Mr. Hoffman agreeing to extend the non-competition restrictions of the Hoffman Employment Agreement for a period of twelve months following the date that his employment terminates with the Company. Merger with TuHURA Biosciences, Inc. On October 4, 2024, at the Company’s Special Meeting of Stockholders, the Company’s stockholders approved the requisite proposals to effect the completion of the Merger pursuant to the Merger Agreement, whereby Merger Sub merged with and into TuHURA, with TuHURA surviving the Merger and becoming direct, wholly owned subsidiary of the Company. Effective at 12:01 a.m. Eastern Time on October 18, 2024, the Company effected the Reverse Stock Split, whereby every 35 shares of issued and outstanding common stock were converted into one share of common stock. Any fractional shares of common stock resulting from the Reverse Stock Split were rounded up to the nearest whole post-Reverse Stock Split share. The Reverse Stock Split did not change the par value of the Company’s common stock or the amount of authorized common stock. Effective at 12:03 a.m. Eastern Time on October 18, 2024, the Company completed the Merger, and effective at 12:04 a.m. Eastern Time on October 18, 2024, the Company changed its name to “TuHURA Biosciences, Inc.” Subject to the terms and conditions of the Merger Agreement, at the effective time of the Merger (the “Effective Time”), (i) each then-outstanding share of TuHURA common stock, par value $ 0.001 per share (the “TuHURA Common Stock”) (other than any shares held in treasury and Dissenting Shares (as defined in the Merger Agreement)) were converted into shares of the Company’s common stock equal to an exchange ratio of 0.1789 (after giving effect to the Reverse Stock Split), (ii) each then-outstanding TuHURA stock option were assumed and converted into an option to purchase shares of the Company’s common stock, subject to certain adjustments as set forth in the Merger Agreement, and (iii) each then-outstanding warrant to purchase shares of TuHURA Common Stock”) was assumed and converted into and exchangeable for a warrant of like tenor entitling the holder to purchase shares of the Company’s common stock, subject to certain adjustments as set forth in the Merger Agreement. Existing Company stockholders received one CVR for each share of common stock held by such stockholder (or, in the case of warrants, each share of common stock of the Company for which such warrant is exercisable into), entitling them to receive, in the aggregate, approximately 1,539,918 shares of the Company's common stock (collectively, the “CVR Shares”) upon achievement of enrollment of a minimum of 10 patients in the REM-001 clinical trial, with such patients each completing 8 weeks of follow-up on or before December 31, 2025 (the “Milestone”). Immediately following the Merger, TuHURA stockholders as of immediately prior to the Merger owned, in aggregate and on a fully-diluted basis, approximately 97.15 % of the Company (or 94.55 % of the Company after giving effect to the issuance of the CVR Shares assuming the Milestone has been achieved) and Company securityholders as of immediately prior to the Merger owned, in aggregate and on a fully-diluted basis, approximately 2.85 % of the Company (or 5.45 % of the Company after giving effect to the issuance of the CVR Shares assuming the Milestone has been achieved). On October 18, 2024, effective immediately prior to the consummation of the Merger, the Company completed a 1-for- 35 reverse stock split (the “2024 Reverse Stock Split”) of its issued and outstanding common stock in connection with the Merger Agreement with TuHURA. As a result of the 2024 Reverse Stock Split, every 35 shares of issued and outstanding common stock were converted into one share of common stock . Any fractional shares of common stock resulting from the 2024 Reverse Stock Split were rounded up to the nearest whole post-2024 Reverse Stock Split share. The 2024 Reverse Stock Split did not change the par value of the Company's common stock or the amount of authorized common stock. All outstanding securities entitling their holders to acquire shares of common stock were adjusted as a result of the 2024 Reverse Stock Split. All common share and per share data are retrospectively restated to give effect to the 2024 Reverse Stock Split for all periods presented herein.

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	3 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
Reverse Stock Split	Reverse stock split On November 10, 2022, the Company filed a Certificate of Change to the Company’s Articles of Incorporation, as amended, in order to effectuate a 1: 50 reverse stock split (the “Reverse Stock Split”) of its issued and outstanding common stock as well as its authorized shares of common stock. As a result of the Reverse Stock Split, every 50 shares of issued and outstanding common stock were converted into one share of common stock with a proportionate reduction in the Company's authorized shares of common stock. Any fractional shares of common stock resulting from the Reverse Stock Split were rounded up to the nearest whole post-Reverse Stock Split share. The Reverse Stock Split did not change the par value of the Company's common stock. All outstanding securities entitling their holders to acquire shares of common stock were adjusted as a result of the Reverse Stock Split. All common share and per share data are retrospectively restated to give effect to the Reverse Stock Split for all periods presented herein.
Basis of Presentation	Basis of presentation The condensed consolidated interim financial statements of the Company have been prepared in accordance with United States Generally Accepted Accounting Principles (“U.S. GAAP”) and are presented in United States dollars. The functional currency of the Company and each of its subsidiaries is the United States dollar. The accompanying condensed consolidated interim financial statements include the accounts of the Company and its wholly-owned subsidiaries, Adgero, Adgero Bio, Del Mar (BC), Callco, and Exchangeco. All intercompany balances and transactions have been eliminated in consolidation. The principal accounting policies applied in the preparation of these condensed consolidated interim financial statements are set out below and have been consistently applied to all periods presented.
Unaudited Interim Financial Data	Unaudited interim financial data The accompanying unaudited condensed consolidated interim financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim financial information. Accordingly, they do not include all of the information and the notes required by U.S. GAAP for complete financial statements. These unaudited condensed consolidated interim financial statements should be read in conjunction with the June 30, 2024, audited consolidated financial statements of the Company included in the Company’s Form 10-K filed with the SEC on October 7, 2024. In the opinion of management, the unaudited condensed consolidated interim financial statements reflect all adjustments, consisting of normal and recurring adjustments, necessary for a fair presentation. The results for three months ended September 30, 2024, are not necessarily indicative of the results to be expected for the fiscal year ending June 30, 2025, or for any other future annual or interim period.
Use of Estimates	Use of estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions about future events that affect the reported amounts of assets, liabilities, expenses, contingent assets, and contingent liabilities as at the end of, or during, the reporting period. Actual results could significantly differ from those estimates. Significant areas requiring management to make estimates include the valuation of equity instruments issued for services, milestone payment liability, and clinical trial accruals. Further details of the nature of these assumptions and conditions may be found in the relevant notes to these condensed consolidated interim financial statements.
Loss Per Share	Loss per share Loss per share is calculated based on the weighted average number of common shares outstanding. For the three-month periods ended September 30, 2024, and 2023, diluted loss per share does not differ from basic loss per share since the effect of the Company’s warrants, stock options, restricted stock units, and convertible preferred shares is anti-dilutive. As of September 30, 2024, potential common shares of 17 (2023 – 20 ) related to outstanding common share warrants, nil (2023 – 1 ) related to outstanding Series C preferred stock warrants, 6 (2023 – 8 ) related to stock options, nil (2023 - 2 ) related to restricted stock units, and nil (2023 – 7 ) relating to outstanding Series C convertible preferred shares were excluded from the calculation of net loss per common share.
Government Assistance	Government assistance Government grants, including grants from similar bodies, are recognized when there is reasonable assurance that the Company has met the requirements of the approved grant program and there is reasonable assurance that the grant will be received. Grants that compensate the Company for expenses incurred are recognized in income or loss in reduction thereof in the same period in which the expenses are recognized. The Company uses a net presentation basis whereby the grant offsets the research and development expenses as it is being recovered under the grant program.
Recently Issued Accounting Standards	Recently issued accounting standards Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company’s condensed consolidated interim financial statements.

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	3 Months Ended
	Sep. 30, 2024
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment, Net	$ Balance, June 30, 2024 674 Depreciation ( 17 ) Balance, September 30, 2024 657

Accounts Payable and Accrued _2

Accounts Payable and Accrued Liabilities (Tables)	3 Months Ended
	Sep. 30, 2024
Payables and Accruals [Abstract]
Schedule of Trade Payables and Accrued Liabilities	September 30, June 30, Trade payables 1,871 1,464 Accrued liabilities 336 743 Balance 2,207 2,207

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	3 Months Ended
	Sep. 30, 2024
Class Of Stock [Line Items]
Summary of Aggregate Information on all Equity Compensation Plans	The following table sets forth the aggregate information on all equity compensation plans as of September 30, 2024: Plan (in thousands, except per share amounts) Number of shares of common stock to be issued upon exercise of outstanding stock options and rights Weighted-average exercise price of stock options and rights Number of shares of common stock remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a)) (2) Equity compensation plans approved by security holders - 2017 Plan (1) 6 749.16 4 Equity compensation plans not approved by security holders - Del Mar (BC) 2013 Amended and Restated Stock Option Plan — 73,881.30 — Totals 6 1,074.40 4 (1) The Del Mar (BC) 2013 Amended and Restated Stock Option Plan refers to the Company’s previous equity compensation plan. (2) The balance of 4 shares of common stock available for issuance under the 2017 Plan as of September 30, 2024, is net of stock options previously exercised.
Schedule of Stock Option Expense	Three months ended 2024 2023 Research and development 37 69 General and administrative 61 91 98 160
Schedule of Unvested Stock Options	Number of Weighted Unvested at June 30, 2024 3 545.01 Vested ( 1 ) 435.36 Unvested at September 30, 2024 2 579.79
Schedule of Restricted Stock Units	Number of Balance – June 30, 2024 2 Vesting of restricted stock units ( 2 ) Balance – September 30, 2024 —
Schedule of Warrants	Number of Weighted Balance – June 30, 2024 19 1,399.72 Expiry of warrants issued for services ( 2 ) 1,750.00 Balance – September 30, 2024 17 1,362.41
Schedule of Changes in Outstanding Warrants	Description of warrants Number Exercise Expiry date 2022 April Investor warrants 9 717.50 April 14, 2027 2022 Investor warrants 7 2,187.50 March 28, 2025 2022 April Agent warrants 1 1,159.20 October 14, 2026 17
Series C Warrants
Class Of Stock [Line Items]
Schedule of Conversion of Series C Preferred Stock to Series C Warrants	Balance Number of Balance, Conversion Preferred Series C-1 Agent Warrants 1,929 ( 1,929 ) — 2,030.00 Preferred Series C-2 Agent Warrants 219 ( 219 ) — 2,124.50 Preferred Series C-3 Agent Warrants 296 ( 296 ) — 2,012.50 2,444 ( 2,444 ) —
Stock options [Member]
Class Of Stock [Line Items]
Summary of Stock Options Currently Outstanding and Exercisable	Exercise price Number Weighted Number 162.93 2 8.92 1 307.65 1 7.84 1 1,067.50 to 1,680.00 2 7.36 2 2,170.00 to 2,397.50 1 2.43 — 6 4
Performance stock units [Member]
Class Of Stock [Line Items]
Schedule of Issuance of Series C Preferred Stock	Series C Preferred Stock Number $ Balance – June 30, 2024 13,668 9,973 Conversion of Series C Preferred stock to common stock ( 13,668 ) ( 9,973 ) Balance – September 30, 2024 — —
Schedule of Series C Preferred Stock Aggregate Dividends	The Company’s Series C Preferred Stock aggregate dividends as of September 30, 2024, were as follows: Series C Dividends Dividend Shares 10% - August 19, 2021 (actual) 1 15% - August 19, 2022 (actual) 1 20% - August 19, 2023 (actual) 1 25% - August 19, 2024 (actual) 2 5

Supplementary Statement of Ca_2

Supplementary Statement of Cash Flows Information (Tables)	3 Months Ended
	Sep. 30, 2024
Supplemental Cash Flow Elements [Abstract]
Schedule of Supplementary Statement of Cash Flows Information	Three months ended 2024 2023 Series C Preferred Stock common stock dividend (note 8) 13 173 Series A Preferred Stock cash dividend in accounts payable and accrued liabilities 2 — Conversion of Series C Preferred Stock to common stock (note 8) 9,973 37 Income taxes paid — — Interest paid — —

Financial instruments (Tables)

Financial instruments (Tables)	3 Months Ended
	Sep. 30, 2024
Investments, All Other Investments [Abstract]
Schedule of Assets and Liabilities Classified , Changes in the Observability of Valuation Inputs Measured using Level 3 Inputs	As of September 30, 2024, the Company’s milestone payment liability was measured using level three inputs. The milestone payment liability relates to contingent milestone payments for the REM-001 program that was acquired in the Adgero merger (note 1). September 30, 2024 Liability Level 1 Level 2 Level 3 Milestone payment liability — — 188 $ Balance – June 30, 2024 186 Change in fair value estimate 2 Balance – September 30, 2024 188

Nature of Operations, Corpora_2

Nature of Operations, Corporate History, and Going Concern and Management Plans - Additional Information (Detail) - USD ($) $ in Thousands			3 Months Ended		12 Months Ended
	Jun. 28, 2023	Aug. 02, 2022	Sep. 30, 2024	Sep. 30, 2023	Jun. 30, 2024
Net loss			$ (2,161)	$ (2,962)
Negative cash flow from operations			(1,889)	$ (1,317)
Cash and cash equivalents			3,020		$ 4,909
Accumulated deficit			$ (162,052)		$ (159,876)
Stock issued during period shares new issues		19,000
Net proceeds available under the stock purchase agreement		$ 2,008
Description of grant funding received			In addition, on June 28, 2023, the Company announced that it had been awarded approximately $2,000 in grant funding to be received over a two-year period for its REM-001 project.
Proceeds from grant funding	$ 2,000
Substantial Doubt about Companys Ability to Continue Going Concern Period			1 year
ATM Facility [Member]
Number of shares issued in transaction					1,519,000
Sale of stock, consideration received on transaction					$ 10,471

Significant Accounting Polici_3

Significant Accounting Policies - Additional Information (Detail)		3 Months Ended
	Nov. 10, 2022 shares	Sep. 30, 2024 shares	Sep. 30, 2023 shares
Reverse stock split	50
Reverse stock split, description		As a result of the Reverse Stock Split, every 50 shares of issued and outstanding common stock were converted into one share of common stock with a proportionate reduction in the Company's authorized shares of common stock.
Reverse stock split, shares	50
Restricted Stock Units [Member]
Anti-dilutive warrants, stock options, performance stock units, and convertible preferred shares related to outstanding			2,000
Series C Preferred Share Warrants [Member]
Anti-dilutive warrants, stock options, performance stock units, and convertible preferred shares related to outstanding			1,000
Series C Convertible Preferred Shares [Member]
Anti-dilutive warrants, stock options, performance stock units, and convertible preferred shares related to outstanding			7,000
Stock options [Member]
Anti-dilutive warrants, stock options, performance stock units, and convertible preferred shares related to outstanding		6,000	8,000
Warrant [Member]
Anti-dilutive warrants, stock options, performance stock units, and convertible preferred shares related to outstanding		17,000	20,000

Clinical Trial Deposit - Additi

Clinical Trial Deposit - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Jun. 30, 2024
Clinical Trial Deposit [Line Items]
Patient enrollment milestones, payments		$ 1,075
Deposits payments			$ 1,075
Clinical trial deposit payments	$ 205		205
Contract Research Organization Termination Cost			$ 1,000

Clinical Trials Grant - Additio

Clinical Trials Grant - Additional Information (Detail) $ in Thousands		3 Months Ended
	Jul. 01, 2023 USD ($) Tranches	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Proceeds from award grants	$ 2,000
Number of tranches | Tranches	2
Research and Development [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Proceeds from award grants		$ 236	$ 13
Tranche One [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Proceeds from award grants	$ 1,250
Tranche Two [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Proceeds from award grants	$ 750

Property and Equipment, Net - S

Property and Equipment, Net - Schedule of Property and Equipment, Net (Detail) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Property, Plant and Equipment [Abstract]
Beginning Balance	$ 674
Depreciation	(17)	$ (15)
Ending Balance	$ 657

Property and Equipment, Net - A

Property and Equipment, Net - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Jun. 30, 2024
Property, Plant and Equipment [Abstract]
Capitalized cost of property and equipment	$ 879		$ 879
Capitalized cost of property and equipment not in use	499
Depreciation expense	$ 17	$ 15

Accounts Payable and Accrued _3

Accounts Payable and Accrued Liabilities - Schedule of Trade Payables and Accrued Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Jun. 30, 2024
Payables and Accruals [Abstract]
Trade payables	$ 1,871	$ 1,464
Accrued liabilities	336	743
Balance	$ 2,207	$ 2,207

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	3 Months Ended
	Sep. 30, 2014	Sep. 30, 2024	Sep. 30, 2023	Jun. 30, 2024	Feb. 13, 2024
Preferred stock, par value		$ 0.001		$ 0.001
Dividends payable			$ 2
Valent Assignment Agreement [Member]
Percentage of net sales					5%
Related Party
Related party payables		$ 50		$ 52
Preferred Stock Series A
Preferred Stock, shares issued		279,000		279,000
Preferred stock, rate of dividend	3%
Valent Technologies LLC [Member]
Loan payable outstanding amount	$ 279
Aggregate accrued interest	$ 29
Dividends payable		$ 2	$ 2
Valent Technologies LLC [Member] | Preferred Stock Series A
Preferred Stock, shares issued	279
Preferred stock, par value	$ 1

Stockholders' Equity - Schedule

Stockholders' Equity - Schedule of Issuance of Series C Preferred Stock (Detail) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Class Of Stock [Line Items]
Conversion of Series C Preferred stock to common stock	$ 9,973	$ 37
Series C Preferred Stock
Class Of Stock [Line Items]
Beginning Balance	$ 9,973
Beginning Balance, shares	13,668
Conversion of series C preferred stock to common stock, shares	(13,668)
Conversion of Series C Preferred stock to common stock	$ (9,973)
Ending Balance	$ 0
Ending Balance, shares	0

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) - USD ($)						1 Months Ended		3 Months Ended		12 Months Ended
	Aug. 19, 2024	Aug. 19, 2023	Aug. 19, 2022	Aug. 02, 2022	Aug. 19, 2021	Aug. 31, 2020	Sep. 30, 2014	Sep. 30, 2024	Sep. 30, 2023	Jun. 30, 2024
Class Of Stock [Line Items]
Preferred stock, par value								$ 0.001		$ 0.001
Stock issued during period shares new issues				19,000
Net proceeds				$ 2,008,000
Common stock, shares issued								1,590,000		1,579,000
Stock option exercise price								$ 1,074.4
Number of stock options outstanding								6,000
Weighted average contractual term								7 years 1 month 28 days	9 years 3 months 3 days
Total expense for restricted stock units issuance								$ 3,000	$ 47,000
Stock-based compensation expense								$ 98,000	160,000
2017 Omnibus Incentive Plan [Member]
Class Of Stock [Line Items]
Common stock, shares issued								13,000
Percentage of fully diluted shares of common stock								8%
Stock options [Member]
Class Of Stock [Line Items]
Aggregate intrinsic value of stock options exercisable								$ 0	0
Unrecognized compensation expense								$ 224,000
Unrecognized compensation expense, term								1 year 9 months 18 days
Aggregate intrinsic value of unvested stock options								$ 0	$ 0
Restricted Stock Units [Member]
Class Of Stock [Line Items]
Stock issued during period shares new issues								2,000	2,000
Stock-based compensation expense								$ 3,000	$ 47,000
Series C Preferred Stock
Class Of Stock [Line Items]
Dividends, Preferred Stock	$ 2,000
Sale of Stock, Price Per Share	$ 0.93
Preferred stock	$ 13,000									$ 9,973,000
Liquidation value										$ 9,973,000
Convertible preferred stock	7,000
Preferred Stock, shares issued										14,000
Stock issued during period shares new issues								2,000
Series C Preferred Stock | Third Anniversary [Member]
Class Of Stock [Line Items]
Common stock dividends percentage		20%
Series C Preferred Stock | Fourth Anniversary [Member]
Class Of Stock [Line Items]
Common stock dividends percentage	25%
Stock issued during period shares new issues								7,000
Series C-1 Preferred Shares [Member]
Class Of Stock [Line Items]
Conversion price								$ 2,030
Series C-2 Preferred Shares [Member]
Class Of Stock [Line Items]
Conversion price								2,124.5
Series C-3 Preferred Shares
Class Of Stock [Line Items]
Conversion price								$ 2,012.5
Preferred Stock Series A
Class Of Stock [Line Items]
Preferred stock								$ 279,000		$ 279,000
Liquidation value								$ 279,000		$ 279,000
Preferred stock, rate of dividend							3%
Preferred Stock, shares issued								279,000		279,000
Change in preferred stock								$ 0	$ 0
Preferred Stock Series A | Exchange Agreement [Member]
Class Of Stock [Line Items]
Preferred stock, rate of dividend							3%
Preferred Stock, shares issued							279,000
Preferred stock, par value							$ 1
Private Placement [Member] | Series C Preferred Stock Warrants
Class Of Stock [Line Items]
Shares issued of common stock for services								2,504
Shares issued, price per share								$ 1,000
ATM Facility [Member]
Class Of Stock [Line Items]
Aggregate number of shares sell										1,519,000
Net proceeds										$ 10,471,000
Merger Agreement [Member] | Series C Preferred Stock | First Anniversary [Member]
Class Of Stock [Line Items]
Common stock dividends percentage					10%
Merger Agreement [Member] | Series C Preferred Stock | Second Anniversary [Member]
Class Of Stock [Line Items]
Common stock dividends percentage			15%
Merger Agreement [Member] | Series C Preferred Stock | Third Anniversary [Member]
Class Of Stock [Line Items]
Common stock dividends percentage		20%
Merger Agreement [Member] | Series C Preferred Stock | Fourth Anniversary [Member]
Class Of Stock [Line Items]
Common stock dividends percentage	25%
Merger Agreement [Member] | Private Placement [Member] | Series C Preferred Stock
Class Of Stock [Line Items]
Shares issued of common stock for services						25,028,000
Shares issued, price per share						$ 1,000
Merger Agreement [Member] | Private Placement [Member] | Series C Preferred Stock | First Anniversary [Member]
Class Of Stock [Line Items]
Common stock dividends percentage								10%
Merger Agreement [Member] | Private Placement [Member] | Series C Preferred Stock | Second Anniversary [Member]
Class Of Stock [Line Items]
Common stock dividends percentage								15%
Merger Agreement [Member] | Private Placement [Member] | Series C Preferred Stock | Third Anniversary [Member]
Class Of Stock [Line Items]
Common stock dividends percentage								20%
Merger Agreement [Member] | Private Placement [Member] | Series C Preferred Stock | Fourth Anniversary [Member]
Class Of Stock [Line Items]
Common stock dividends percentage								25%

Stockholders' Equity - Schedu_2

Stockholders' Equity - Schedule of Series C Preferred Stock Aggregate Dividends (Detail) - Series C Preferred Stock shares in Thousands	3 Months Ended
	Sep. 30, 2024 shares
Class Of Stock [Line Items]
Dividend Shares (in thousands)	5
10% - August 19, 2021 [Member]
Class Of Stock [Line Items]
Dividend Shares (in thousands)	1
15% - August 19, 2022 [Member]
Class Of Stock [Line Items]
Dividend Shares (in thousands)	1
20% - August 19, 2023 [Member]
Class Of Stock [Line Items]
Dividend Shares (in thousands)	1
25% - August 19, 2024 [Member]
Class Of Stock [Line Items]
Dividend Shares (in thousands)	2

Stockholders' Equity - Summary

Stockholders' Equity - Summary of Aggregate Information on all Equity Compensation Plans (Details) shares in Thousands	3 Months Ended
	Sep. 30, 2024 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares of common stock to be issued upon exercise of outstanding stock options and rights	6
Weighted-average exercise price of stock options and rights | $ / shares	$ 1,074.4
Number of shares of common stock remaining available for future issuance under equity compensation plans	4
Equity Compensation Plans Approved by Security Holders - 2017 Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares of common stock to be issued upon exercise of outstanding stock options and rights	6
Weighted-average exercise price of stock options and rights | $ / shares	$ 749.16
Number of shares of common stock remaining available for future issuance under equity compensation plans	4
Equity Compensation Plans Not Approved by Security Holders - Del Mar (BC) 2013 Amended and Restated Stock Option Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Weighted-average exercise price of stock options and rights | $ / shares	$ 73,881.3

Stockholders' Equity - Summar_2

Stockholders' Equity - Summary of Aggregate Information on all Equity Compensation Plans (Parenthetical) (Details) shares in Thousands	Sep. 30, 2024 shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares of common stock remaining available for future issuance under equity compensation plans	4
Omnibus Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares of common stock remaining available for future issuance under equity compensation plans	4

Stockholders' Equity - Summar_3

Stockholders' Equity - Summary of Stock Options Outstanding and Exercisable (Detail)	3 Months Ended
	Sep. 30, 2024 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of stock options outstanding	6,000
Stock options exercisable	4,000
Exercise Price One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price | $ / shares	$ 162.93
Number of stock options outstanding	2,000
Weighted average remaining contractual life (years)	8 years 11 months 1 day
Stock options exercisable	1,000
Exercise Price Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price | $ / shares	$ 307.65
Number of stock options outstanding	1,000
Weighted average remaining contractual life (years)	7 years 10 months 2 days
Stock options exercisable	1,000
Exercise Price Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of stock options outstanding	2,000
Weighted average remaining contractual life (years)	7 years 4 months 9 days
Stock options exercisable	2,000
Exercise Price Three [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price | $ / shares	$ 1,067.5
Exercise Price Three [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price | $ / shares	$ 1,680
Exercise Price Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of stock options outstanding	1,000
Weighted average remaining contractual life (years)	2 years 5 months 4 days
Exercise Price Four [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price | $ / shares	$ 2,170
Exercise Price Four [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price | $ / shares	$ 2,397.5

Stockholders' Equity - Schedu_3

Stockholders' Equity - Schedule of Stock Option Expense (Detail) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 98	$ 160
Research and Development [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	37	69
General and Administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 61	$ 91

Stockholders' Equity - Schedu_4

Stockholders' Equity - Schedule of Unvested Stock Options (Detail)	3 Months Ended
	Sep. 30, 2024 $ / shares shares
Equity [Abstract]
Beginning balance | shares	3,000
Vesting of restricted stock units | shares	(1,000)
Ending balance | shares	2,000
Beginning balance | $ / shares	$ 545.01
Vested | $ / shares	435.36
Ending balance | $ / shares	$ 579.79

Stockholders' Equity - Schedu_5

Stockholders' Equity - Schedule of Restricted Stock Units (Details)	3 Months Ended
	Sep. 30, 2024 shares
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]
Beginning balance	3,000
Vesting of restricted stock units	(1,000)
Ending balance	2,000
Restricted Stock Units [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]
Beginning balance	2,000
Vesting of restricted stock units	(2,000)
Ending balance	0

Stockholders' Equity - Schedu_6

Stockholders' Equity - Schedule of Warrants (Detail)	3 Months Ended
	Sep. 30, 2024 $ / shares shares
Stock option exercise price	$ 1,074.4
Common Stock Warrants [Member]
Balance - June 30, 2024 | shares	19,000
Balance - September 30, 2024 | shares	17,000
Beginning balance	$ 1,399.72
Ending balance	$ 1,362.41
Common Stock Warrants [Member] | Issued For Services One [Member]
Expiry of warrants | shares	(2,000)
Expired	$ 1,750

Stockholders' Equity - Schedu_7

Stockholders' Equity - Schedule of Outstanding Warrants (Detail) - Warrant [Member]	3 Months Ended
	Sep. 30, 2024 $ / shares shares
Number	17,000
Investor [Member]
Number	9,000
Warrants exercise price | $ / shares	$ 717.5
Expiry date	Apr. 14, 2027
InvestorOne [Member]
Number	7,000
Warrants exercise price | $ / shares	$ 2,187.5
Expiry date	Mar. 28, 2025
Agent [Member]
Number	1,000
Warrants exercise price | $ / shares	$ 1,159.2
Expiry date	Oct. 14, 2026

Stockholders' Equity - Schedu_8

Stockholders' Equity - Schedule of Outstanding Series C Agent Warrants (Detail) - Series C Warrants	3 Months Ended
	Sep. 30, 2024 $ / shares shares
Balance	2,444
Number of Warrants Exercised	(2,444)
Balance	0
Preferred Series C-1 Agent Warrants [Member]
Balance	219
Number of Warrants Exercised	(219)
Balance	0
Conversion price | $ / shares	$ 2,124.5
Preferred Series C-2 Agent Warrants [Member]
Balance	1,929
Number of Warrants Exercised	(1,929)
Balance	0
Conversion price | $ / shares	$ 2,030
Preferred Series C-3 Agent Warrants [Member]
Balance	296
Number of Warrants Exercised	(296)
Balance	0
Conversion price | $ / shares	$ 2,012.5

Supplementary Statement of Ca_3

Supplementary Statement of Cash Flows Information - Schedule of Supplementary Statement of Cash Flows Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Supplemental Cash Flow Elements [Abstract]
Preferred Stock common stock dividend (note 8)	$ 13	$ 173
Conversion of Series C Preferred Stock to common stock (note 8)	9,973	37
Preferred Stock Series C
Supplemental Cash Flow Elements [Abstract]
Preferred Stock common stock dividend (note 8)	13	$ 173
Conversion of Series C Preferred Stock to common stock (note 8)	(9,973)
Preferred Stock Series A
Supplemental Cash Flow Elements [Abstract]
Series A Preferred Stock cash dividend in accounts payable and accrued liabilities	$ 2

Financial instruments -Schedule

Financial instruments -Schedule of Assets and Liabilities Classified , Changes in the Observability of Valuation Inputs Measured using Level 3 Inputs (Details) $ in Thousands	3 Months Ended
	Sep. 30, 2024 USD ($)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Balance	$ 186
Change in fair value estimate	2
Balance	188
Level 3 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Milestone payment liability	$ 188

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail)			3 Months Ended
	Oct. 18, 2024 Patients $ / shares shares	Nov. 10, 2022 shares	Sep. 30, 2024 $ / shares	Jun. 30, 2024 $ / shares
Subsequent Event [Line Items]
Reverse stock split		50
Reverse stock split, description			As a result of the Reverse Stock Split, every 50 shares of issued and outstanding common stock were converted into one share of common stock with a proportionate reduction in the Company's authorized shares of common stock.
Reverse stock split, shares | shares		50
Common stock, par value | $ / shares			$ 0.001	$ 0.001
TuHURA Biosciences, Inc. [Member]
Subsequent Event [Line Items]
Reverse stock split, description			As a result of the 2024 Reverse Stock Split, every 35 shares of issued and outstanding common stock were converted into one share of common stock
Description of contingent value rights			Existing Company stockholders received one CVR for each share of common stock held by such stockholder (or, in the case of warrants, each share of common stock of the Company for which such warrant is exercisable into), entitling them to receive, in the aggregate, approximately 1,539,918 shares of the Company's common stock (collectively, the “CVR Shares”) upon achievement of enrollment of a minimum of 10 patients in the REM-001 clinical trial, with such patients each completing 8 weeks of follow-up on or before December 31, 2025 (the “Milestone”).
Subsequent Event [Member]
Subsequent Event [Line Items]
Percentage of shares expected to collectively owned	2.85%
Percentage of shares underlying the CVR	5.45%
Subsequent Event [Member] | TuHURA Biosciences, Inc. [Member]
Subsequent Event [Line Items]
Reverse stock split	35
Reverse stock split, shares | shares	35
Common stock, par value | $ / shares	$ 0.001
Common stock equal to exchange ratio | $ / shares	$ 0.1789
Contingent value rights entitled to receive common stock, shares | shares	1,539,918,000
Minimum of number of patients enrolled | Patients	10
Percentage of shares expected to collectively owned	97.15%
Percentage of shares underlying the CVR	94.55%